表紙
市場調查報告書

遺傳基因檢驗的全球市場 - 分析與預測:2020年∼2030年

Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

出版商 BIS Research Inc. 商品編碼 948002
出版日期 內容資訊 英文 236 Pages
商品交期: 最快1-2個工作天內
價格
遺傳基因檢驗的全球市場 - 分析與預測:2020年∼2030年 Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030
出版日期: 2020年06月30日內容資訊: 英文 236 Pages
簡介

全球遺傳基因檢驗市場,預計至2030年達到673億9000萬美元。

本報告提供全球遺傳基因檢驗市場相關調查分析,市場概要,市場分析與預測,主要企業等相關的系統性資訊。

目錄

第1章 產品定義

第2章 調查範圍

第3章 調查手法

第4章 競爭情形

  • M&A
  • 產品的銷售
  • 相乘活性
  • 事業擴大活動等
  • 市場佔有率分析
  • 成長佔有率分析

第5章 遺傳基因檢驗:概要

  • 遺傳基因檢驗現況
  • 市場足跡與未來的可能性

第6章 市場動態

  • 概要
  • 影響分析
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會

第7章 產業考察

  • 相關法規
    • 美國
    • 歐洲
    • 亞太地區
  • 償付方案

第8章 全球遺傳基因檢驗市場:各產品

  • 概要
  • 套件、消耗品
  • 服務
  • 其他

第9章 全球遺傳基因檢驗市場:各標本類型

  • 概要
  • 腫瘤組織
  • 骨髓
  • 唾液
  • 血液
  • 其他標本類型

第10章 全球遺傳基因檢驗市場:各技術

  • 概要
  • 次世代定序(NGS)
  • 聚合酵素鏈鎖反應(PCR)
  • 免疫組織化學(IHC)
  • In situ雜合反應(ISH)
  • 微陣列技術
  • 其他技術

第11章 全球遺傳基因檢驗市場:各腫瘤遺傳基因檢驗類型

  • 概要
  • 乳癌
  • 肺癌症
  • 前列腺癌症
  • 大腸癌症
  • 黑色素瘤
  • 其他腫瘤遺傳基因檢驗

第12章 全球遺傳基因檢驗市場:各心臟病遺傳基因檢驗類型

  • 概要
  • 心肌病
  • 主動脈症
  • 心律不整
  • 其他心臟病遺傳基因檢驗

第13章 全球遺傳基因檢驗市場:各神經遺傳基因檢驗類型

  • 概要
  • 癲癇
  • 神經退化性疾病
  • 神經肌肉障礙
  • 其他神經遺傳基因檢驗

第14章 全球遺傳基因檢驗市場:各其他遺傳基因檢驗類型

  • 新生兒篩檢
  • 產前篩檢(NIPT)、胚胎著床前檢驗
  • 罕見疾病檢驗
  • 直銷 (DTC) 檢驗

第15章 全球遺傳基因檢驗市場:各應用領域

  • 學術、研究
  • 臨床診斷
  • 藥物研發
  • 監測、篩檢

第16章 全球遺傳基因檢驗市場:各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 西班牙
    • 俄羅斯
    • 荷蘭
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 新加坡
    • 其他的亞太地區
  • 南美
    • 巴西
    • 墨西哥
    • 其他南美
  • 其他全球地區

第17章 企業簡介

  • Agilent Technologies, Inc.
  • Ambry Genetics
  • Beijing Genomics Institute (BGI)
  • CENTOGENE AG
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific Inc.
  • 新興企業
目錄
Product Code: BHP0930SA

"Global Hereditary Genetic Testing Market to Reach $67.39 Billion by 2030."

Market Segmentation

  • Product Type: Kits, Consumables, and Services
  • Sample Type: Tumor Tissue, Blood, Saliva, Bone Marrow
  • Technology: Next Generation Sequencing, Polymerase Chain Reaction,Immunohistochemistry, In-situ Hybridization, Microarray Techniques
  • Oncology Genetic Testing: Breast, Colorectal,Prostate, Lung, Melanoma
  • Cardiology Genetic Testing: Cardiomyopathy,Aortopathy, Arrythmia
  • Neurology Genetic Testing: Epilepsy, Neurodegenerative Disorders, Neuromuscular Disorders
  • Other Genetic Testing: Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing
  • Application Area: Academia and Research Centers, Clinical Diagnostics, Drug Discovery, Monitoring and Screening

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, France, Italy, U.K., Spain, Russia, Netherlands
  • Asia-Pacific - Japan, China, India, Australia, Singapore
  • Latin America - Brazil, Mexico
  • Rest-of-the-World - Kingdom of Saudi Arabia (K.S.A.), U.A.E., Palestine, Algeria

Cross Segmentation

  • North America - Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing
  • Europe - Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing
  • Asia-Pacific - Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing
  • Latin America - Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing
  • Rest-of-the-World - Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing

Growth Drivers

  • Rising Prevalence of Genetic Disorders
  • Increasing Prevalence of Various Types of Cancer, Globally
  • Increasing Research Funding in the Field of Genomics

Market Challenges

  • Expensive Sequencing Procedures and Their Applications in Medical Treatments
  • High Capital Requirement Hampering the Expansion of Global Reach
  • Stringent Regulatory Standards

Market Opportunities

  • Technological Advancements for Exome Sequencing
  • Rise of Direct-to-Consumer (DTC) Testing Services
  • Massive Scope for Adoption of NGS-Based in Emerging Nations

Key Companies Profiled

Agilent Technologies, Inc., Ambry Genetics, Beijing Genomics Institute (BGI), CENTOGENE AG, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Inc. Illumina, Inc. , Laboratory Corporation of America Holdings, Myriad Genetics, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

  • What are the possible long-term and short-term impacts of hereditary genetic testing on the human health continuum?
  • What are the major market drivers, challenges, and opportunities in the hereditary genetic testing?
  • What are the key development strategies which are being implemented by the major players in order to sustain in the competitive market?
  • What are the key regulatory implications in the developed and developing regions for the global hereditary genetic testing market?
  • How are service-based companies impacting the growth of the global hereditary genetic testing industry and further shaping up future trends?
  • How each segment of the market is expected to grow during the forecast period from 2020 to 2030?
  • Who are the leading players with significant offerings to the global hereditary genetic testing market? What is the expected market dominance for each of these leading players?
  • Which companies are anticipated to be highly disruptive in the future, and why?
  • What are the needs that are yet to be met by the global hereditary genetic testing market with respect to the application area?
  • What are the dynamics of various application areas and countries are impacting the global hereditary genetic testing market?
  • What are the new market opportunities of various technologies influencing the growth of the global hereditary genetic testing market?

Market Overview

The hereditary genetic testinghas grown significantly since the technology was first commercialized, but it is important to quantify that growth and describe future trends. The genome testing industry is proliferating, and its growth is expected to continue at its torrid pace. However, there are significant challenges that may dampen future growth if not addressed.

Our healthcare experts have found hereditary genetic testing to be one of the most rapidly evolving technologies, and the global market for hereditary genetic testing is predicted to grow at a CAGR of 13.59% over the forecast period of 2020-2030.

The unmet clinical needs for better tools to predict, diagnose, treat, and monitor disease are acting as significant factors driving the growth of sequencing industry. Other factors driving the growth include the increased understanding of the molecular basis of disease, patient demand, industry investment, and regulations that allow marketing of tests without FDA approval.

Despite rapid advanced sequencing industry growth, there are several key issues that are needed to be addressed to facilitate future growth. The relatively high total costs of delivering sequencing test results compared with other technology platforms, and limited coverage by payers, are the key challenges to the growth of this industry. Whole genome and exome sequencing remain relatively costly requiring initial equipment investment, specialized workforce requirements, and time-intensive variant interpretation.

Within the research report, the market is segmented on the basis of oncology genetic testing, cardiology genetic testing, neurology genetic testing, product, sample, application area, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of next generation sequencing on the global level has created a buzz among companies to invest in the products and services of whole genome and exome sequencing. Due to the diverse product portfolio and intense market penetration, whole genome and exome has been a pioneer in this field and been a significant competitor in this market.

On the basis of region, North America holds the largest share, due to improved healthcare infrastructure, rise in per capita income, and improvisedreimbursement policies in the region. Apart from this, Latin America and the Asia-Pacific region are anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Hereditary Genetic Testing
  • 1.2 Inclusion and Exclusion

2 Research Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Primary Data Sources
  • 3.2 Secondary Data Sources
  • 3.3 Market Estimation Model
  • 3.4 Criteria for Company Profiling

4 Competitive Landscape

  • 4.1 Mergers and Acquisitions
  • 4.2 Product Launches
  • 4.3 Synergistic Activities
  • 4.4 Business Expansion Activities and Others
  • 4.5 Market Share Analysis
  • 4.6 Growth Share Analysis

5 Hereditary Genetic Testing: Overview

  • 5.1 Current State of Hereditary Genetic Testing
  • 5.2 Market Footprint and Future Potential

6 Market Dynamics

  • 6.1 Overview
  • 6.2 Impact Analysis
  • 6.3 Market Drivers
    • 6.3.1 Rising Prevalence of Genetic Disorders
    • 6.3.2 Increasing Prevalence of Various Types of Cancer, Globally
    • 6.3.3 Increasing Research Funding in the Field of Genomics
  • 6.4 Market Restrains
    • 6.4.1 Expensive Sequencing Procedures and Their Applications in Medical Treatments
    • 6.4.2 High Capital Requirement Hampering the Expansion of Global Reach
    • 6.4.3 Stringent Regulatory Standards
  • 6.5 Market Opportunities
    • 6.5.1 Technological Advancements for Exome Sequencing
    • 6.5.2 Rise of Direct-to-Consumer (DTC) Testing Services
    • 6.5.3 Massive Scope for Adoption of NGS-Based in Emerging Nations

7 Industry Insights

  • 7.1 Legal and Regulatory Framework
    • 7.1.1 United States
    • 7.1.2 Europe
      • 7.1.2.1 Germany
      • 7.1.2.2 France
      • 7.1.2.3 Italy
    • 7.1.3 Asia-Pacific
      • 7.1.3.1 China
      • 7.1.3.2 Japan
      • 7.1.3.3 Australia
  • 7.2 Reimbursement Scenario

8 Global Hereditary Genetic Testing Market (by Product)

  • 8.1 Overview
  • 8.2 Kits and Consumables
  • 8.3 Services
  • 8.4 Others

9 Global Hereditary Genetic Testing Market (by Sample Type)

  • 9.1 Overview
  • 9.2 Tumor Tissue
  • 9.3 Bone Marrow
  • 9.4 Saliva
  • 9.5 Blood
  • 9.6 Other Sample Types

10 Global Hereditary Genetic Testing Market (by Technology)

  • 10.1 Overview
  • 10.2 Next Generation Sequencing (NGS)
  • 10.3 Polymerase Chain Reaction (PCR)
  • 10.4 Immunohistochemistry (IHC)
  • 10.5 In-Situ Hybridization (ISH)
  • 10.6 Microarray Techniques
  • 10.7 Other Technologies

11 Global Hereditary Genetic Testing Market (by Oncology Genetic Testing Type)

  • 11.1 Overview
  • 11.2 Breast Cancer
  • 11.3 Lung Cancer
  • 11.4 Prostate Cancer
  • 11.5 Colorectal Cancer
  • 11.6 Melanoma
  • 11.7 Other Oncology Hereditary Genetic Testing

12 Global Hereditary Genetic Testing Market (by Cardiology Genetic Testing Type)

  • 12.1 Overview
  • 12.2 Cardiomyopathy
  • 12.3 Aortopathy
  • 12.4 Arrhythmia
  • 12.5 Other Cardiology Hereditary Genetic Testing

13 Global Hereditary Genetic Testing Market (by Neurology Genetic Testing Type)

  • 13.1 Overview
  • 13.2 Epilepsy
  • 13.3 Neurodegenerative Disorders
  • 13.4 Neuromuscular Disorders
  • 13.5 Other Neurology Hereditary Genetic Testing

14 Global Hereditary Genetic Testing Market (by Other Genetic Testing type)

  • 14.1 Newborn Screening
  • 14.2 Prenatal Screening (NIPT) and Preimplantation Testing
  • 14.3 Rare Disease Testing
  • 14.4 Direct-to-Consumer Testing

15 Global Hereditary Genetic Testing Market (by Application Area)

  • 15.1 Academic and Research
  • 15.2 Clinical Diagnostics
  • 15.3 Drug discovery
  • 15.4 Monitoring and Screening

16 Global Hereditary Genetic Testing Market (by Region)

  • 16.1 Overview
  • 16.2 North America
    • 16.2.1 U.S.
    • 16.2.2 Canada
  • 16.3 Europe
    • 16.3.1 Germany
    • 16.3.2 France
    • 16.3.3 Italy
    • 16.3.4 U.K.
    • 16.3.5 Spain
    • 16.3.6 Russia
    • 16.3.7 Netherlands
    • 16.3.8 Rest-of-Europe
  • 16.4 Asia-Pacific
    • 16.4.1 China
    • 16.4.2 Japan
    • 16.4.3 India
    • 16.4.4 Australia
    • 16.4.5 Singapore
    • 16.4.6 Rest-of-APAC
  • 16.5 Latin America
    • 16.5.1 Brazil
    • 16.5.2 Mexico
    • 16.5.3 Rest-of-Latin America
  • 16.6 Rest-of-the-World (RoW)

17 Company Profiles

  • 17.1 Overview
  • 17.2 Agilent Technologies, Inc.
    • 17.2.1 Company Overview
    • 17.2.2 Role of Agilent Technologies, Inc. in the Global Hereditary Genetic Testing Market
    • 17.2.3 Financials
    • 17.2.4 Key Insights About Financial Health of the Company
    • 17.2.5 SWOT Analysis
  • 17.3 Ambry Genetics
    • 17.3.1 Company Overview
    • 17.3.2 Role of Ambry Genetics in the Global Hereditary Genetic Testing Market
    • 17.3.3 SWOT Analysis
  • 17.4 Beijing Genomics Institute (BGI)
    • 17.4.1 Company Overview
    • 17.4.2 Role of BGI in the in the Global Hereditary Genetic Testing Market
    • 17.4.3 SWOT Analysis
  • 17.5 CENTOGENE AG
    • 17.5.1 Company Overview
    • 17.5.2 Role of CENTOGENE AG in the Global Hereditary Genetic Testing Market
    • 17.5.3 SWOT Analysis
  • 17.6 Eurofins Scientific SE
    • 17.6.1 Company Overview
    • 17.6.2 Role of Eurofins Scientific SE in the Global Hereditary Genetic Testing Market
    • 17.6.3 Financials
    • 17.6.4 SWOT Analysis
  • 17.7 F. Hoffmann-La Roche Ltd
    • 17.7.1 Company Overview
    • 17.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Hereditary Genetic Testing Market
    • 17.7.3 Financials
    • 17.7.4 Key Insights About Financial Health of the Company
    • 17.7.5 SWOT Analysis
  • 17.8 Illumina, Inc.
    • 17.8.1 Company Overview
    • 17.8.2 Role of Illumina, Inc. in the Global Hereditary Genetic Testing Market
    • 17.8.3 Financials
    • 17.8.4 Key Insights About Financial Health of the Company
    • 17.8.5 SWOT Analysis
  • 17.9 Laboratory Corporation of America Holdings
    • 17.9.1 Company Overview
    • 17.9.2 Role of Laboratory Corporation of America Holdings in the Global Hereditary Genetic Testing Market
    • 17.9.3 Financials
    • 17.9.4 SWOT Analysis
  • 17.1 Myriad Genetics, Inc.
    • 17.10.1 Company Overview
    • 17.10.2 Role of Myriad Genetics, Inc. in the Global Hereditary Genetic Testing Market
    • 17.10.3 SWOT Analysis
  • 17.11 PerkinElmer, Inc.
    • 17.11.1 Company Overview
    • 17.11.2 Role of PerkinElmer Inc, in Global Hereditary Genetic Testing Market
    • 17.11.3 Financials
    • 17.11.4 Key Insights About Financial Health of the Company
    • 17.11.5 SWOT Analysis
  • 17.12 Quest Diagnostics Incorporated
    • 17.12.1 Company Overview
    • 17.12.2 Role of Quest Diagnostics Incorporated in the Global Hereditary Genetic Testing Market
    • 17.12.3 Financials
    • 17.12.4 SWOT Analysis
  • 17.13 Thermo Fisher Scientific Inc.
    • 17.13.1 Company Overview
    • 17.13.2 Role of Thermo Fisher Scientific Inc. in the Global Hereditary Genetic Testing Market
    • 17.13.3 Financials
    • 17.13.4 Key Insights About Financial Health of the Company
    • 17.13.5 SWOT Analysis
  • 17.14 Emerging Companies
    • 17.14.1 COLOR
      • 17.14.1.1 Company Overview
    • 17.14.2 Natera, Inc.
      • 17.14.2.1 Company Overview

List of Tables

  • Table 7.1: Regulatory Bodies Governing Hereditary Genetic Testing
  • Table 8.1: Key Products and Application in Global Hereditary Genetic Testing Market
  • Table 11.1: Available Hereditary Genetic Tests for Breast Cancer
  • Table 11.2: Available Hereditary Genetic Tests for Lung Cancer
  • Table 11.3: Available Hereditary Genetic Tests for Lung Cancer
  • Table 11.4: Available Hereditary Genetic Tests for Colorectal Cancer
  • Table 11.5: Available Hereditary Genetic Tests for Melanoma
  • Table 11.6: Available Hereditary Genetic Tests for Others
  • Table 12.1: Available Hereditary Genetic Tests for Cardiomyopathy
  • Table 12.2: Available Hereditary Genetic Tests for Aortopathy
  • Table 12.3: Available Hereditary Genetic Tests for Arrhythmia
  • Table 12.4: Available Hereditary Genetic Tests for Others
  • Table 13.1: Available Hereditary Genetic Tests for Epilepsy
  • Table 13.2: Available Hereditary Genetic Tests for Neurodegenerative Disorders
  • Table 13.3: Available Hereditary Genetic Tests for Neuromuscular Disorders
  • Table 13.4: Available Hereditary Genetic Tests for Others
  • Table 17.1: BIS Insight
  • Table 17.2: BIS Insight

List of Figures

  • Figure 1: Launched Hereditary Genetic Test Units (2017)
  • Figure 2: Impact of Market Drivers and Market Restraints on the Global Hereditary Genetic Testing Market
  • Figure 3: Global Hereditary Genetic Testing Market (by Product), $Billion, 2019 vs. 2030
  • Figure 4: Global Hereditary Genetic Testing Market (by Application Area), $Billion, 2019 vs. 2030
  • Figure 5: Global Hereditary Genetic Testing Market Snapshot, $Billion, 2019 and 2030
  • Figure 2.1: Global Hereditary Genetic Testing Market Segmentation
  • Figure 3.1: Global Hereditary Genetic Testing Market Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 4.1: Share of Key Developments and Strategies, January 2017-April 2020
  • Figure 4.2: Number of Product Launches (by Company), January 2017-April 2020
  • Figure 4.3: Synergistic Activities Share (by Company), January 2017-April 2020
  • Figure 4.4: Business Expansion Activities Share (by Company), January 2017-April 2020
  • Figure 4.5: Market Share Analysis for the Global Hereditary Genetic Testing Market, 2019
  • Figure 4.6: Growth Share Matrix for Global Hereditary Genetic Testing Market (by Company), 2018-2019
  • Figure 6.1: Impact Analysis
  • Figure 6.2: People Suffering from CF (Cystic Fibrosis), 2002-2017:
  • Figure 6.3: Number of Deaths (in Millions) by Different Forms of Cancer, 2018
  • Figure 7.1: Overall Reimbursement Scenario: 2018
  • Figure 8.1: Global Hereditary Genetic Testing Market (by Product)
  • Figure 8.2: Global Hereditary Genetic Testing Market (Kits), 2019-2030
  • Figure 8.3: Global Hereditary Genetic Testing Market (Consumables), 2019-2030
  • Figure 8.4: Global Hereditary Genetic Testing Market (Services), 2019-2030
  • Figure 8.5: Global Hereditary Genetic Testing Market (Others), 2019-2030
  • Figure 9.1: Global Hereditary Genetic Testing Market (by Sample Type)
  • Figure 9.2: Global Hereditary Genetic Testing Market (Tumor Tissue), 2019-2030
  • Figure 9.3: Global Hereditary Genetic Testing Market (Bone Marrow), 2019-2030
  • Figure 9.4: Global Hereditary Genetic Testing Market (Saliva), 2019-2030
  • Figure 9.5: Global Hereditary Genetic Testing Market (Blood), 2019-2030
  • Figure 9.6: Global Hereditary Genetic Testing Market (Other Sample Types), 2019-2030
  • Figure 10.1: Global Hereditary Genetic Testing Market (by Technology)
  • Figure 10.2: Global Hereditary Genetic Testing Market (Next Generation Sequencing), 2019-2030
  • Figure 10.3: Global Hereditary Genetic Testing Market (Polymerase Chain Reaction), 2019-2030
  • Figure 10.4: Global Hereditary Genetic Testing Market (Immunohistochemistry), 2019-2030
  • Figure 10.5: Global Hereditary Genetic Testing Market (In-Situ Hybridization), 2019-2030
  • Figure 10.6: Global Hereditary Genetic Testing Market (Microarray Techniques), 2019-2030
  • Figure 10.7: Global Hereditary Genetic Testing Market (Other Technologies), 2019-2030
  • Figure 11.1: Global Hereditary Genetic Testing Market (Oncology Genetic Testing Type), 2019-2030
  • Figure 11.2: Global Hereditary Genetic Testing Market (Breast Cancer), 2019-2030
  • Figure 11.3: Global Hereditary Genetic Testing Market (Lung Cancer), 2019-2030
  • Figure 11.4: Global Hereditary Genetic Testing Market (Prostate Cancer), 2019-2030
  • Figure 11.5: Global Hereditary Genetic Testing Market (Colorectal Cancer), 2019-2030
  • Figure 11.6: Global Hereditary Genetic Testing Market (Melanoma), 2019-2030
  • Figure 11.7: Global Hereditary Genetic Testing Market (Other Oncology Hereditary Genetic Testing), 2019-2030
  • Figure 12.1: Global Hereditary Genetic Testing Market (Cardiology Genetic Testing Type), 2019-2030
  • Figure 12.2: Global Hereditary Genetic Testing Market (Cardiomyopathy), 2019-2030
  • Figure 12.3: Global Hereditary Genetic Testing Market (Aortopathy), 2019-2030
  • Figure 12.4: Global Hereditary Genetic Testing Market (Arrhythmia), 2019-2030
  • Figure 12.5: Global Hereditary Genetic Testing Market (Other Cardiology Hereditary Genetic Testing), 2019-2030
  • Figure 13.1: Global Hereditary Genetic Testing Market (Neurology Genetic Testing Type), 2019-2030
  • Figure 13.2: Global Hereditary Genetic Testing Market (Epilepsy), 2019-2030
  • Figure 13.3: Global Hereditary Genetic Testing Market (Neurodegenerative Disorders), 2019-2030
  • Figure 13.4: Global Hereditary Genetic Testing Market (Neuromuscular Disorders), 2019-2030
  • Figure 13.5: Global Hereditary Genetic Testing Market (Other Neurology Hereditary Genetic Testing), 2019-2030
  • Figure 14.1: Figure xx: Global Hereditary Genetic Testing Market (Newborn Screening), 2019-2030
  • Figure 14.2: Global Hereditary Genetic Testing Market (Prenatal Screening and Preimplantation Testing), 2019-2030
  • Figure 14.3: Global Hereditary Genetic Testing Market (Rare Disease Testing), 2019-2030
  • Figure 14.4: Global Hereditary Genetic Testing Market (Direct-to-Consumer Testing), 2019-2030
  • Figure 15.1: Global Hereditary Genetic Testing Market (Academic and Research), 2019-2030
  • Figure 15.2: Global Hereditary Genetic Testing Market (Clinical Diagnostics), 2019-2030
  • Figure 15.3: Global Hereditary Genetic Testing Market (Drug Discovery), 2019-2030
  • Figure 15.4: Global Hereditary Genetic Testing Market (Monitoring and Screening), 2019-2030
  • Figure 16.1: Global Hereditary Genetic Testing Market (by Region), 2019 and 2030
  • Figure 16.2: Global Hereditary Genetic TestingMarket (by Region), 2019-2030
  • Figure 16.3: Global Hereditary Genetic Testing Market Share (by Region), 2019
  • Figure 16.4: Global Hereditary Genetic Testing Market Share (by Region), 2030
  • Figure 16.5: North America Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.6: North America: Market Dynamics
  • Figure 16.7: North America Hereditary Genetic Testing Market (by Testing Type), 2019-2030
  • Figure 16.8: North America Hereditary Genetic Testing Market (by Country), 2019-2030
  • Figure 16.9: U.S. Hereditary Genetic TestingMarket, 2019-2030
  • Figure 16.10: Canada Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.11: Europe Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.12: Europe: Market Dynamics
  • Figure 16.13: Europe Hereditary Genetic Testing Market (by Testing Type), 2019-2030
  • Figure 16.14: Europe Hereditary Genetic Testing Market (by Country), 2019-2030
  • Figure 16.15: Germany Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.16: France Hereditary Genetic testing Market, 2019-2030
  • Figure 16.17: Italy Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.18: U.K. Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.19: Spain Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.20: Russia Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.21: Netherlands Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.22: Rest-of-Europe Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.23: Asia-Pacific Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.24: APAC: Market Dynamics
  • Figure 16.25: Asia-Pacific Hereditary Genetic Testing Market (by Testing Type), 2019-2030
  • Figure 16.26: APAC Hereditary Genetic Testing Market (by Country), 2019-2030
  • Figure 16.27: China Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.28: Japan Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.29: India Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.30: Australia Hereditary Genetic TestingMarket, 2019-2030
  • Figure 16.31: Singapore Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.32: RoAPAC Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.33: Latin America Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.34: Latin America: Market Dynamics
  • Figure 16.35: Latin America Hereditary Genetic Testing Market (by Testing Type), 2019-2030
  • Figure 16.36: Latin America Hereditary Genetic Testing Market (by Country), 2019-2030
  • Figure 16.37: Brazil Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.38: Mexico Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.39: Rest-of-Latin America Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.40: RoW Hereditary Genetic Testing Market, 2019-2030
  • Figure 16.41: Rest-of-the-World (RoW) Hereditary Genetic Testing Market (by Testing Type), 2019-2030
  • Figure 17.1: Total Number of Companies Profiled
  • Figure 17.2: Agilent Technologies, Inc.: Product Portfolio
  • Figure 17.3: Agilent Technologies, Inc.: Overall Financials, 2017-2019
  • Figure 17.4: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
  • Figure 17.5: Agilent Technologies, Inc.: Revenue (by Region), 2016-2018
  • Figure 17.6: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
  • Figure 17.7: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 17.8: Ambry Genetics: Product Portfolio
  • Figure 17.9: Ambry Genetics: SWOT Analysis
  • Figure 17.10: BGI: Product Portfolio
  • Figure 17.11: BGI: SWOT Analysis
  • Figure 17.12: CENTOGENE AG: Overall Product Portfolio
  • Figure 17.13: CENTOGENE AG: SWOT Analysis
  • Figure 17.14: Eurofins Scientific SE: Overall Financials, 2016-2018
  • Figure 17.15: Eurofins Scientific SE: Revenue (by Region), 2016-2018
  • Figure 17.16: Eurofins Scientific SE.: SWOT Analysis
  • Figure 17.17: F. Hoffmann-La Roche Ltd:Product Portfolio
  • Figure 17.18: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 17.19: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
  • Figure 17.20: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
  • Figure 17.21: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
  • Figure 17.22: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 17.23: Illumina, Inc.: Product Portfolio
  • Figure 17.24: Illumina, Inc.: Overall Financials, 2017-2019
  • Figure 17.25: Illumina, Inc.: Revenue (by Segment), 2017-2019
  • Figure 17.26: Illumina, Inc.: R&D Expenditure, 2017-2019
  • Figure 17.27: Illumina, Inc.: SWOT Analysis
  • Figure 17.28: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
  • Figure 17.29: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
  • Figure 17.30: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
  • Figure 17.31: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 17.32: Myriad Genetics, Inc.: Product Portfolio
  • Figure 17.33: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 17.34: PerkinElmer, Inc.: Overall Financials, 2017-2019
  • Figure 17.35: PerkinElmer, Inc.: Revenue (by Segment), 2017-2019
  • Figure 17.36: PerkinElmer, Inc.: Revenue (by Region), 2018-2019
  • Figure 17.37: PerkinElmer, Inc.: R&D Expenditure,2017-2019
  • Figure 17.38: PerkinElmer, Inc.: SWOT Analysis
  • Figure 17.39: Product Portfolio: Quest Diagnostics Incorporated
  • Figure 17.40: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
  • Figure 17.41: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 17.42: Thermo Fisher Scientific Inc.: Product Portfolio
  • Figure 17.43: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
  • Figure 17.44: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
  • Figure 17.45: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
  • Figure 17.46: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
  • Figure 17.47: Thermo Fisher Scientific Inc.: SWOT Analysis